CN112839651A - 联合疗法 - Google Patents

联合疗法 Download PDF

Info

Publication number
CN112839651A
CN112839651A CN201980067618.0A CN201980067618A CN112839651A CN 112839651 A CN112839651 A CN 112839651A CN 201980067618 A CN201980067618 A CN 201980067618A CN 112839651 A CN112839651 A CN 112839651A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
solvate
prodrug
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980067618.0A
Other languages
English (en)
Chinese (zh)
Inventor
丹尼尔·P·戈尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lite Strategy Inc
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of CN112839651A publication Critical patent/CN112839651A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980067618.0A 2018-08-14 2019-08-13 联合疗法 Pending CN112839651A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862718925P 2018-08-14 2018-08-14
US62/718,925 2018-08-14
PCT/US2019/046405 WO2020036995A1 (en) 2018-08-14 2019-08-13 Combination therapy

Publications (1)

Publication Number Publication Date
CN112839651A true CN112839651A (zh) 2021-05-25

Family

ID=69525833

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980067618.0A Pending CN112839651A (zh) 2018-08-14 2019-08-13 联合疗法

Country Status (9)

Country Link
US (1) US20210161909A1 (https=)
JP (1) JP2021534114A (https=)
CN (1) CN112839651A (https=)
AU (1) AU2019322858A1 (https=)
EA (1) EA202190360A1 (https=)
IL (1) IL280729A (https=)
MX (1) MX2021001764A (https=)
TW (1) TW202021592A (https=)
WO (1) WO2020036995A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118949002A (zh) * 2024-10-15 2024-11-15 杭州阿克索生物科技有限责任公司 一种宫颈癌细胞抑制组合物及其制备方法和应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
AU2023228576A1 (en) * 2022-03-01 2024-09-26 Mei Pharma, Inc. Combination therapy of pi3k inhibitor and pd-1 inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103582636A (zh) * 2011-03-28 2014-02-12 梅制药公司 （α-取代的芳烷基氨基和杂芳基烷基氨基）嘧啶基和1,3,5-三嗪基苯并咪唑、含有其的药物组合物以及这些化合物在治疗增生性疾病中的用途
WO2017172826A1 (en) * 2016-03-28 2017-10-05 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer
CN111212643A (zh) * 2017-08-14 2020-05-29 梅制药公司 联合疗法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563596B2 (en) * 2006-06-21 2013-10-22 Piramal Enterprises Limited Enantiomerically pure compounds for the treatment of proliferative disorders
WO2014055647A1 (en) * 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
TW201618773A (zh) * 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
CN109982687A (zh) * 2016-09-19 2019-07-05 梅制药公司 联合疗法
US11304953B2 (en) * 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103582636A (zh) * 2011-03-28 2014-02-12 梅制药公司 （α-取代的芳烷基氨基和杂芳基烷基氨基）嘧啶基和1,3,5-三嗪基苯并咪唑、含有其的药物组合物以及这些化合物在治疗增生性疾病中的用途
WO2017172826A1 (en) * 2016-03-28 2017-10-05 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer
CN111212643A (zh) * 2017-08-14 2020-05-29 梅制药公司 联合疗法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118949002A (zh) * 2024-10-15 2024-11-15 杭州阿克索生物科技有限责任公司 一种宫颈癌细胞抑制组合物及其制备方法和应用

Also Published As

Publication number Publication date
MX2021001764A (es) 2021-04-19
IL280729A (en) 2021-03-25
WO2020036995A1 (en) 2020-02-20
US20210161909A1 (en) 2021-06-03
AU2019322858A1 (en) 2021-04-01
EA202190360A1 (ru) 2021-07-15
JP2021534114A (ja) 2021-12-09
TW202021592A (zh) 2020-06-16

Similar Documents

Publication Publication Date Title
CN112165939A (zh) 联合疗法
TWI807150B (zh) 苯并咪唑衍生物及其醫藥組合物及使用方法
JP2023001404A (ja) 併用療法
US11351176B2 (en) Combination therapy
JP2023022081A (ja) 併用療法
WO2020132563A1 (en) Combination therapy
CN112839651A (zh) 联合疗法
CN112888441A (zh) B细胞恶性肿瘤的治疗
EA040851B1 (ru) Комбинированная терапия

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210525

WD01 Invention patent application deemed withdrawn after publication